Role of the cholinergic system in the pathology and treatment of schizophrenia

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Arlington, VA, USA (2000).
   Google Scholar
• Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu. Rev. Genomics Hum. Genet.5, 189–218 (2004)
   PubMed Web of Science ®Google Scholar
• Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Psychopharmacology The Fourth Generation of Progress. Bloom FJ, Kupfer DJ (Eds). Raven Press, NY, USA 1215–1229 (1995)
   Google Scholar
• Jablensky A. Subtyping schizophrenia: implications for genetic research. Mol. Psychiatry11(9), 815–836 (2006).
   PubMed Web of Science ®Google Scholar
• Hallmayer JF, Kalaydjieva L, Badcock J et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am. J. Hum. Genet.77(3), 468–476 (2005).
   PubMed Web of Science ®Google Scholar
• Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Aust. NZ J. Psychiatry30(1), 20–37 (1996).
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov.3(4), 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res.79(1), 59–68 (2005).
   PubMed Web of Science ®Google Scholar
• Wooley DW, Shaw E. A biological and pharmacological suggestion about certain mental disorders. Proc. Natl Acad. Sci. USA40, 228–231 (1954).
   PubMed Web of Science ®Google Scholar
• KimJS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett.20(3), 379–382 (1980).
   PubMed Web of Science ®Google Scholar
• Luisada PV. The phencyclidine psychosis: phenomenology and treatment. NIDA Res. Monogr.21, 241–253 (1978).
   Google Scholar
• Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D2 receptor antagonism to glutamate NMDA facilitation. Clin. Ther.27(Suppl. 1), S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad. Sci.1003, 138–158 (2003).
   PubMed Web of Science ®Google Scholar
• Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology1(3), 179–186 (1988).
   PubMed Web of Science ®Google Scholar
• Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacolol. Sci. DOI: 10.1176/appi.ajp.2008.06091591 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry153(3), 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res.72(1), 41–51 (2004).
   PubMed Web of Science ®Google Scholar
• Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res.72(1), 21–28 (2004).
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology12(3), 426–445 (1998).
   PubMed Web of Science ®Google Scholar
• Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther.27(Suppl. 1), S25–S37 (2005).
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry12(10), 904–922 (2007).
   PubMed Web of Science ®Google Scholar
• Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Archiv. Eur. J. Physiol.446(1), 17–29 (2003).
   PubMed Web of Science ®Google Scholar
• Wessler I, Kirkpatrick C, Racké K. The cholinergic “pitfall”: acetylcholine, a universal cell molecule in biological systems, including humans. Clin. Exp. Pharmacol. Physiol.26(3), 198–205 (1999).
   PubMed Web of Science ®Google Scholar
• Shepherd GM. Neurobiology. Oxford University Press, Inc., Oxford, UK (1998).
   Google Scholar
• Okuda T, Haga T, Kanai Y, Endou H, Ishihara T, Katsura I. Identification and characterization of the high-affinity choline transporter. Nat. Neurosci.3(2), 120–125 (2000).
   PubMed Web of Science ®Google Scholar
• Masson J, Sagne C, Hamon M, Mestikawy SE. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev.51(3), 439–464 (1999).
   PubMed Web of Science ®Google Scholar
• Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Hardman JG, Limbard LE, Gilman AG (Eds). McGraw-Hill, NY, USA 115–155 (2001).
   Google Scholar
• Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci.22(6), 273–280 (1999).
   PubMed Web of Science ®Google Scholar
• Dale HH. The action of certain esters and ethers of choline and their relation to muscarine. J. Pharmacol. Exp. Ther.6(2), 147–190 (1914).
   Google Scholar
• Steinlein OK, Bertrand D. Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem. Pharmacol.76(10), 1175–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Pereira EF, Mike A, Eisenberg HM, Maelicke A, Alkondon M. Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behav. Brain Res.113(1–2), 131–141 (2000).
   PubMed Web of Science ®Google Scholar
• Zolles G, Wagner E, Lampert A, Sutor B. Functional expression of nicotinic acetylcholine receptors in rat neocortical layer 5 pyramidal cells. Cereb. Cortex DOI: 10.1093/cercor/bhn158 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci.27(9), 482–491 (2006).
   PubMed Web of Science ®Google Scholar
• Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science237(4814), 527–532 (1987).
   PubMed Web of Science ®Google Scholar
• Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther.117(2), 232–243 (2008).
   PubMed Web of Science ®Google Scholar
• Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc. Natl Acad. Sci. USA90(11), 5194–5198 (1993).
   PubMedGoogle Scholar
• Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci.22(5), 1709–1717 (2002).
   PubMed Web of Science ®Google Scholar
• Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer’s disease. J. Neurochem.64(4), 1888–1891 (1995).
   PubMed Web of Science ®Google Scholar
• Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl Acad. Sci. USA87(18), 7050–7054 (1990).
   PubMedGoogle Scholar
• Wess J, Duttaroy A, Zhang W et al. M1–M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Recept. Channels9(4), 279–290 (2003).
   PubMedGoogle Scholar
• Dean B, Bymaster FP, Scarr E. Muscarinic receptors in schizophrenia. Curr. Mol. Med.3(5), 419–426 (2003).
   PubMed Web of Science ®Google Scholar
• Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of m (1) muscarinic receptors. Neuropsychopharmacology30(11), 1986–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur. J. Pharmacol.596(1-3), 89–97 (2008).
   PubMedGoogle Scholar
• Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. J. Pharmacol. Exp. Ther.327(1), 161–167 (2008).
   PubMedGoogle Scholar
• Grilli M, Patti L, Robino F, Zappettini S, Raiteri M, Marchi M. Release-enhancing pre-synaptic muscarinic and nicotinic receptors co-exist and interact on dopaminergic nerve endings of rat nucleus accumbens. J. Neurochem. DOI: 10.1111/j.1471–4159.2008.05307.x (2008) (Epub ahead of print).
   Google Scholar
• Lester DB, Miller AD, Pate TD, Blaha CD. Midbrain acetylcholine and glutamate receptors modulate accumbal dopamine release. Neuroreport19(9), 991–995 (2008).
   PubMedGoogle Scholar
• Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl Acad. Sci. USA95(19), 11465–11470 (1998).
   PubMedGoogle Scholar
• Shinoe T, Matsui M, Taketo MM, Manabe T. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J. Neurosci.25(48), 11194–11200 (2005).
   PubMed Web of Science ®Google Scholar
• Kremin T, Gerber D, Giocomo LM, Huang SY, Tonegawa S, Hasselmo ME. Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABA(B) receptors. Neurobiol. Learn. Mem.85(2), 153–163 (2006).
   PubMedGoogle Scholar
• Seol GH, Ziburkus J, Huang S et al. Neuromodulators control the polarity of spike-timing-dependent synaptic plasticity. Neuron55(6), 919–929 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen LH, Thale T, Tissenbaum MJ. Acetylcholine treatment of schizophrenia. Arch. Neurol. Psychiatry51, 171–175 (1944).
   Google Scholar
• Forrer GR. Atropine toxicity in the treatment of mental disease. Am. J. Psychiatry108(2), 107–112 (1951).
   PubMedGoogle Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry27(7), 1081–1090 (2003).
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry12(3), 232–246 (2006).
   PubMedGoogle Scholar
• Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry161(1), 116–124 (2004).
   PubMed Web of Science ®Google Scholar
• Friedhoff AJ, Alpert M. A dopaminergic–cholinergic mechanism in production of psychotic symptoms. Biol. Psychiatry6(2), 165–169 (1973).
   PubMedGoogle Scholar
• Janowsky DS, Davis JM, El Yousef MK, Sekerke HJ. Antagonistic effects of physostigmine and methylphenidate in man. Am. J. Psychiatry130(12), 1370–1376 (1973).
   PubMed Web of Science ®Google Scholar
• Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch. Gen. Psychiatry46(8), 745–753 (1989).
   PubMed Web of Science ®Google Scholar
• Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology12(1), 3–16 (1995).
   PubMed Web of Science ®Google Scholar
• Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatry Serv.46(5), 435–436 (1995).
   PubMed Web of Science ®Google Scholar
• Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry32(7), 607–616 (1992).
   PubMed Web of Science ®Google Scholar
• Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J. Psychopharmacol.18(4), 457–474 (2004).
   PubMed Web of Science ®Google Scholar
• Freedman R, Coon H, Myles-Worsley M et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl Acad. Sci. USA94(2), 587–592 (1997).
   PubMed Web of Science ®Google Scholar
• Perl O, Ilani T, Strous RD, Lapidus R, Fuchs S. The α7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J.17(13), 1948–1950 (2003).
   PubMedGoogle Scholar
• Perl O, Strous RD, Dranikov A, Chen R, Fuchs S. Low levels of α7-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity. Neuropsychobiology53(2), 88–93 (2006).
   PubMed Web of Science ®Google Scholar
• Martin-Ruiz CM, Haroutunian VH, Long P et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol. Psychiatry54(11), 1222–1233 (2003).
   PubMed Web of Science ®Google Scholar
• De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Regulation of α7-nicotinic receptor subunit and α7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr. Scand.114(3), 211–215 (2006).
   PubMed Web of Science ®Google Scholar
• Lipska BK, Mitkus S, Caruso M et al. RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum. Mol. Genet.15(18), 2804–2812 (2006).
   PubMedGoogle Scholar
• Mathew SV, Law AJ, Lipska BK et al. α7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum. Mol. Genet.16(23), 2921–2932 (2007).
   PubMedGoogle Scholar
• Severance EG, Yolken RH. Novel α7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav.7(1), 37–45 (2008).
   PubMed Web of Science ®Google Scholar
• Freedman R, Leonard S, Waldo M, Gault J, Olincy A, Adler LE. Characterization of allelic variants at chromosome 15q14 in schizophrenia. Genes Brain Behav.5, 14–22 (2006).
   PubMedGoogle Scholar
• Gault J, Hopkins J, Berger R et al. Comparison of polymorphisms in the a7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am. J. Med. Genet. B Neuropsychiatr. Genet.123B(1), 39–49 (2003).
   PubMedGoogle Scholar
• Li CH, Liao HM, Chen CH. Identification of molecular variants at the promoter region of the human α7 neuronal nicotinic acetylcholine receptor subunit gene but lack of association with schizophrenia. Neurosci. Lett.372(1–2), 1–5 (2004).
   PubMedGoogle Scholar
• Zammit S, Spurlock G, Williams H et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry191, 402–407 (2007).
   PubMed Web of Science ®Google Scholar
• Iwata Y, Nakajima M, Yamada K et al. Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia. Neurosci. Res.57(2), 194–202 (2007).
   PubMedGoogle Scholar
• De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL. Linkage of M5 muscarinic and α7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology50(2), 124–127 (2004).
   PubMedGoogle Scholar
• De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL. Evidence of association between smoking and α7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology29(8), 1522–1526 (2004).
   PubMed Web of Science ®Google Scholar
• Houy E, Raux G, Thibaut F et al. The promoter -194 C polymorphism of the nicotinic α 7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol. Psychiatry9(3), 320–322 (2004).
   PubMed Web of Science ®Google Scholar
• Martin LF, Leonard S, Hall MH, Tregellas JR, Freedman R, Olincy A. Sensory gating and α-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(5), 611–614 (2007).
   PubMed Web of Science ®Google Scholar
• Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl.)138(3–4), 217–230 (1998).
   PubMed Web of Science ®Google Scholar
• Wonnacott S, Sidhpura N, Balfour DJ. Nicotine: from molecular mechanisms to behaviour. Curr. Opin. Pharmacol.5(1), 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Breese CR, Lee MJ, Adams CE et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology23(4), 351–364 (2000).
   PubMed Web of Science ®Google Scholar
• De Luca V, Voineskos S, Wong G, Kennedy JL. Genetic interaction between α4 and β2 subunits of high affinity nicotinic receptor: analysis in schizophrenia. Exp. Brain Res.174(2), 292–296 (2006).
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikeda M, Kitajima T et al. Genetic association analysis of tagging SNPs in α4 and β2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2 ) with schizophrenia in the Japanese population. J. Neural Transm.115, 1457–1461 (2008).
   PubMedGoogle Scholar
• Faraone SV, Su J, Taylor L, Wilcox M, Van Eerdewegh P, Tsuang MT. A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Hum. Hered.57(2), 59–68 (2004).
   PubMed Web of Science ®Google Scholar
• Voineskos S, De Luca V, Mensah A, Vincent JB, Potapova N, Kennedy JL. Association of α4β2 nicotinic receptor and heavy smoking in schizophrenia. J. Psychiatry Neurosci.32(6), 412 (2007).
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Takenouchi T, Azuma R et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology28(3), 542–551 (2003).
   PubMed Web of Science ®Google Scholar
• Koike K, Hashimoto K, Takai N et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res.76(1), 67–72 (2005).
   PubMed Web of Science ®Google Scholar
• Adler LE, Cawthra EM, Donovan KA et al. Improved P50 auditory gating with ondansetron in medicated schizophrenia patients. Am. J. Psychiatry162(2), 386–388 (2005).
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry63(6), 630–638 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman R, Olincy A, Buchanan RW et al. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry165(8), 1040–1047 (2008).
   PubMed Web of Science ®Google Scholar
• Barr RS, Culhane MA, Jubelt LE et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology33(3), 480–490 (2008).
   PubMed Web of Science ®Google Scholar
• Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin. Neuropharmacol.28(3), 139–141 (2005).
   PubMed Web of Science ®Google Scholar
• Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry60(6), 530–533 (2006).
   PubMed Web of Science ®Google Scholar
• Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol.22(2), 63–68 (2007).
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Conley RR, Dickinson D et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry165(1), 82–89 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly DL, McMahon RP, Weiner E et al. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr. Res.103(1–3), 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Dyer MA, Freudenreich O, Culhane MA et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr. Res.102(1–3), 88–95 (2008).
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Schwartz BL, Schooler NR, Rosse RB, Mastropaolo J, Gaskins B. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained α7 nicotinic agonist strategy. Clin. Neuropharmacol.31(1), 34–39 (2008).
   PubMedGoogle Scholar
• Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry36(9), 927–934 (1979).
   PubMed Web of Science ®Google Scholar
• Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther.260(2), 576–580 (1992).
   PubMed Web of Science ®Google Scholar
• Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci.64(25), 2351–2358 (1999).
   PubMed Web of Science ®Google Scholar
• ZavitsanouK, Katsifis A, Mattner F, Xu-Feng H. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology29(3), 619–625 (2004).
   PubMed Web of Science ®Google Scholar
• Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J. Neurosci. Res.81(6), 883–890 (2005).
   PubMedGoogle Scholar
• Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci. Lett.379(3), 164–168 (2005).
   PubMed Web of Science ®Google Scholar
• Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic (1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry7(10), 1083–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.119(1), 2–6 (2003).
   Google Scholar
• Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res. Bull.65(5), 397–403 (2005).
   PubMedGoogle Scholar
• Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 225–233 (2007).
   PubMed Web of Science ®Google Scholar
• Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPγS binding in schizophrenia. Life Sci.78(11), 1231–1237 (2006).
   PubMedGoogle Scholar
• Tzavara ET, Bymaster FP, Felder CC et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol. Psychiatry8(7), 673–679 (2003).
   PubMed Web of Science ®Google Scholar
• Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry61, 1161–1170 (2007).
   PubMedGoogle Scholar
• Raedler TJ, Knable MB, Jones DW et al.In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry160(1), 118–127 (2003).
   PubMed Web of Science ®Google Scholar
• Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B. Decreased cortical muscarinic receoptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry DOI: 10.1038/mp.2008.28 (2008) (Epub ahead of print).
   Google Scholar
• McKinney M, Anderson D, Vella-Rountree L. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems. Mol. Pharmacol.35(1), 39–47 (1989).
   PubMedGoogle Scholar
• Salles J, Wallace MA, Fain JN. Differential effects of alkylating agents on the multiple muscarinic receptor subtypes linked to activation of phospholipase C by carbachol in rat brain cortical membranes. J. Pharmacol. Exp. Ther.264(2), 521–529 (1993).
   PubMedGoogle Scholar
• Fisher SK, Snider RM. Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas. Mol. Pharmacol.32(1), 81–90 (1987).
   PubMedGoogle Scholar
• Weiner DM, Meltzer HY, Veinbergs I et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl.)177(1–2), 207–216 (2004).
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry165(8), 1033–1039
   PubMedGoogle Scholar
• Shannon HE, Bymaster FP, Calligaro DO et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther.269(1), 271–281 (1994).
   PubMed Web of Science ®Google Scholar
• Watson J, Brough S, Coldwell MC et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br. J. Pharmacol.125(7), 1413–1420 (1998).
   PubMed Web of Science ®Google Scholar
• Böhm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem. J.322(1), 1–18 (1997).
   PubMed Web of Science ®Google Scholar
• May LT, Lin Y, Sexton PM, Christopoulos A. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J. Pharmacol. Exp. Ther.312(1), 382–390 (2005).
   PubMedGoogle Scholar
• Langmead CJ, Austin NE, Branch CL et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-21. Br. J. Pharmacol.154(5), 1104–1115 (2008).
   PubMed Web of Science ®Google Scholar
• Chan WY, McKinzie DL, Bose S et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl Acad. Sci. USA105(31), 10978–10983 (2008).
   PubMed Web of Science ®Google Scholar
• Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J. Neurochem.107(5), 1188–1195 (2008).
   PubMed Web of Science ®Google Scholar
• Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin. Neuropharmacol.26(6), 317–321 (2003).
   PubMed Web of Science ®Google Scholar
• MendelsohnE, Rosenthal M, Bohiri Y, Werber E, Kotler M, Strous RD. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int. Clin. Psychopharmacol.19(6), 319–324 (2004).
   PubMed Web of Science ®Google Scholar
• Aasen I, Kumari V, Sharma T. Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. J. Clin. Psychopharmacol.25(4), 311–317 (2005).
   PubMed Web of Science ®Google Scholar
• Kumari V, Aasen I, Ffytche D, Williams SCR, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage29(2), 545–556 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr. Res.85(1–3), 73–83 (2006).
   PubMed Web of Science ®Google Scholar
• Chouinard S, Stip E, Poulin J et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr. Med. Res. Opin.23(3), 575–583 (2007).
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Herz L, Deckersbach T et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology181(2), 358–363 (2005).
   PubMed Web of Science ®Google Scholar
• Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cognit. Neuropsychiatry12(5), 412–421 (2007).
   PubMedGoogle Scholar
• Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol.30(1), 3–12 (2007).
   PubMed Web of Science ®Google Scholar
• Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol.21(4), 421–427 (2007).
   PubMedGoogle Scholar
• Keefe RSE, Malhotra AK, Meltzer HY et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo//practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology33(6), 1217–1228 (2007).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Gerami M, Noroozian M et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry32(8), 1810–1815 (2008).
   PubMed Web of Science ®Google Scholar
• Sanchez-MorlaEM, Garcia-Jimenez MA, Barabash A et al. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr. Scand.117(4), 313–318 (2008).
   PubMed Web of Science ®Google Scholar
• Erskine FF, Ellis JR, Ellis KA et al. Evidence for synergistic modulation of early information processing by nicotinic and muscarinic receptors in humans. Hum. Psychopharmacol.19(7), 503–509 (2004).
   PubMedGoogle Scholar
• Green A, Ellis KA, Ellis J et al. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol. Biochem. Behav.81(3), 575–584 (2005).
   PubMedGoogle Scholar
• Ellis JR, Ellis KA, Bartholomeusz CF et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int. J. Neuropsychopharmacol.9(2), 175–189 (2006).
   PubMed Web of Science ®Google Scholar
• Spalding TA, Trotter C, Skjarbak N et al. Discovery of an ectopic activation site on the m1 muscarinic receptor. Mol. Pharmacol.61(6), 1297–1302 (2002).
   PubMedGoogle Scholar
• Langmead CJ, Fry VAH, Forbes IT et al. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic m1 receptor: direct pharmacological evidence that ac-42 is an allosteric agonist. Mol. Pharmacol.69(1), 236–246 (2006).
   PubMedGoogle Scholar
• Acker BA, Jacobsen EJ, Rogers BN et al. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carnonamide as an agonist of the α7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett.18(12), 3611–3615 (2008).
   PubMedGoogle Scholar
• Timmermann DB, Gronlien JH, Kohlhaas KL et al. An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J. Pharmacol. Exp. Ther.323(1), 294–307 (2007).
   PubMed Web of Science ®Google Scholar
• Watson J, Langmead C, Davies C, Hagan J. Challenges in developing cholinergic agents for the treatment of schizophrenia. Int. J. Neuropsychopharmacol.11(Suppl. 1), 31 (2008)
   Google Scholar
• Brady AE, Jones CK, Bridges TM et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther.327(3), 941–953 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RJ. G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J. Pharmacol. Exp. Ther.327(2), 365–374 (2008).
   PubMedGoogle Scholar